Panobinostat

Generic Name: Panobinostat

Brand Names: Farydak

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃N_₃O_₂

CAS Number: 404950-80-7

Unique Ingredient Identifier: 9647FM7Y3Z

Background: Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is mar...

Indication: Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.

Associated Conditions: Refractory Multiple Myeloma

Associated Therapies: -

Clinical Trials

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Alectinib
Drug: Cetuximab
Drug: Crizotinib
Drug: Dasatinib
Drug: Everolimus
Drug: Encorafenib
Drug: Gemcitabine
Drug: Idelalisib
Drug: Larotrectinib
Drug: Methotrexate
Drug: Palbociclib
Drug: Panobinostat
Drug: Pembrolizumab
Drug: Petrozumab
Drug: Trastuzumab
Drug: Talazoparib
Drug: Venetoclax

First Posted Date: 2023-02-13

Last Posted Date: 2023-02-21

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 40

Registration Number: NCT05725200

Locations: 🇳🇴
Oslo University Hospital, Oslo, Norway

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

Phase 2

Terminated

Conditions: Rhabdoid Tumor
Atypical Teratoid/Rhabdoid Tumor
Recurrent Brain Tumor, Childhood
Malignant Rhabdoid Tumor

Interventions: Drug: Panobinostat

First Posted Date: 2021-05-24

Last Posted Date: 2022-06-08

Lead Sponsor: Australian & New Zealand Children's Haematology/Oncology Group

Target Recruit Count: 25

Registration Number: NCT04897880

Locations: 🇦🇺
John Hunter Children's Hospital, New Lambton, New South Wales, Australia
🇺🇸
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, United States
🇦🇺
Sydney Children's Hospital, Randwick, New South Wales, Australia

and more 8 locations

Phase I Study of Marizomib + Panobinostat for Children With DIPG

Phase 1

Terminated

Conditions: Diffuse Intrinsic Pontine Glioma
Pediatric Brainstem Glioma
Pediatric Brainstem Gliosarcoma, Recurrent
Pediatric Cancer
Pediatric Brain Tumor
Diffuse Glioma

Interventions: Drug: Marizomib
Drug: Panobinostat

First Posted Date: 2020-04-10

Last Posted Date: 2024-02-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 4

Registration Number: NCT04341311

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Phase 3

Terminated

Conditions: Acute Myeloid Leukaemia (AML)
Myelodysplastic Syndromes (MDS)

Interventions: Drug: Panobinostat

First Posted Date: 2020-03-30

Last Posted Date: 2023-02-16

Lead Sponsor: Goethe University

Target Recruit Count: 52

Registration Number: NCT04326764

Locations: 🇩🇪
Universitätsklinikum Leipzig, Leipzig, Thüringen, Germany
🇩🇪
Robert Bosch Krankenhaus, Stuttgart, Baden-Württemberg, Germany
🇳🇱
Amsterdam University Medical Center - VUMC, Amsterdam, Netherlands

and more 16 locations

PDR001 + Panobinostat for Melanoma and NSCLC

Phase 1

Withdrawn

Conditions: Melanoma
Non Small Cell Lung Cancer

Interventions: Drug: PDR001
Drug: Panobinostat

First Posted Date: 2019-06-11

Last Posted Date: 2019-10-04

Lead Sponsor: Muhammad Furqan

Registration Number: NCT03982134

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1

Terminated

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat

First Posted Date: 2019-03-18

Last Posted Date: 2024-03-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03878524

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas

Phase 2

Withdrawn

Conditions: Diffuse Intrinsic Pontine Glioma
Glioma

Interventions: Drug: Panobinostat
Drug: Everolimus

First Posted Date: 2018-08-15

Last Posted Date: 2019-08-19

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT03632317

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Refractory Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma

Interventions: Drug: Carfilzomib
Other: Chemosensitivity Assay
Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Drug: Panobinostat

First Posted Date: 2017-08-21

Last Posted Date: 2022-05-09

Lead Sponsor: University of Washington

Target Recruit Count: 9

Registration Number: NCT03256045

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Phase 2

Withdrawn

Conditions: Lymphoma

Interventions: Drug: Palifermin
Drug: Panobinostat
Drug: Gemcitabine
Drug: Busulfan
Drug: Melphalan
Drug: Rituximab
Drug: Dexamethasone
Drug: Caphosol
Drug: Glutamine
Other: Oral Cryotherapy (ice chips)
Drug: Pyridoxine
Biological: Stem Cell Infusion
Drug: G-CSF

First Posted Date: 2016-11-11

Last Posted Date: 2017-04-21

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT02961816

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Phase 1

Completed

Conditions: Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

Interventions: Biological: PDR001
Drug: QBM076
Drug: HDM201
Drug: LCL161
Drug: Everolimus
Drug: Panobinostat

First Posted Date: 2016-09-07

Last Posted Date: 2023-01-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 298

Registration Number: NCT02890069

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy